SKIN ATLAS · ACTIVE INGREDIENT · 4 MIN. READING TIME

Tranexamic Acid & Kojic Acid: Dual Tyrosinase Inhibition in Brightening Complexes

Tranexamic acid and kojic acid are among the best-characterized depigmenting active ingredients in modern cosmetic formulations — both inhibit the key enzyme tyrosinase, but do so via mechanistically distinct pathways. In combination, a synergistic overlapping effect is created, which at the same time poses a critical formulation challenge: pH drift in aqueous brightening matrices can compromise the stability of both molecules and significantly reduce the overall effectiveness of the complex. Understanding this interaction is a prerequisite for evidence-based product development and informed application.

Term and Origin

Tranexamic acid (TXA) is a synthetic amino acid structurally derived from lysine. Originally developed in 1962 by Japanese biochemist Utako Okamoto as an antifibrinolytic — a substance to inhibit blood clot dissolution — its depigmenting effect was discovered decades later when treated melasma patients reported noticeable lightening. Since then, TXA has become indispensable in dermatological hyperpigmentation management and is used orally, intravenously, or topically depending on the application context. In accordance with EU Cosmetics Regulation 1223/2009, topical application at appropriate concentrations (typically 2–5%) is permitted without restrictions.

Kojic acid (5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one) is a natural metabolite of various mold species of the genera Aspergillus and Penicillium, as well as a byproduct of food fermentation processes such as sake, soy sauce, and miso. Its depigmenting property was systematically described in the 1980s; since then, it has been considered one of the most commonly used natural tyrosinase inhibitors in brightening formulations. The name is derived from the Japanese term kōji (麹), the mold substrate of traditional fermentation processes. Both substances are closely linked to the research field of dark spots, as their primary indication is in the treatment of hyperpigmentation, melasma, and post-inflammatory hyperpigmentation (PIH).

The combination of both active ingredients in a single brightening complex is a relatively young formulation strategy that has only become practically feasible with improved stability methods and modern encapsulation technologies. In this context, the term "pH-drift" refers to the gradual shift in the formulation's pH value during storage or application — a phenomenon particularly relevant for kojic acid, as the molecule is stable within a pH window of 4.5–6.0, but tends to oxidize and brown with even slight deviations.

Characteristics & Mechanism of Action

Tyrosinase is the key enzyme in melanogenesis: it catalyzes the hydroxylation of L-tyrosine to L-DOPA and the subsequent oxidation to dopachinone, the immediate precursor of all melanin subtypes. Kojic acid inhibits tyrosinase by chelating the catalytically essential copper ion in the enzyme's active site — a competitive mechanism with high selectivity. This copper-chelate effect is well documented and also explains the high activity of kojic acid at comparatively low concentrations (0.5–2% in finished formulations). The substance thus acts directly at the enzymatic source of pigment synthesis.

Tranexamic acid, on the other hand, acts further upstream in the melanogenesis signaling pathway. Its primary mechanism consists of competitively inhibiting the binding of plasminogen to keratinocytes: plasmin physiologically stimulates the release of arachidonic acid, which leads to the activation of melanocytes via the prostaglandin E2 signaling pathway. TXA disrupts this paracrine signaling cascade, reduces UV-induced melanocyte stimulation, and simultaneously reduces local inflammatory tone — an effect particularly relevant for the treatment of inflammation-associated hyperpigmentation (PIH). Additionally, a direct structural similarity of TXA to tyrosine is discussed, which could enable partial inhibition of tyrosinase through substrate competition, although this contribution is considered secondary.

The superposition of both mechanisms — enzymatic blockade via copper chelation (kojic acid) and paracrine signal interruption via plasminogen inhibition (tranexamic acid) — theoretically creates a complementary broad-spectrum coverage of melanogenesis that would not be achievable with a single active ingredient. However, the formulation's breaking point lies in the pH range: tranexamic acid is stable in aqueous solution over a broad pH range (approx. 3.0–8.0), while kojic acid rapidly oxidizes at pH > 6.5 and is converted into a brown compound (Kojic Acid Oxidation Product). In a common aqueous matrix, tranexamic acid — depending on the counterion and buffer choice — can contribute to pH drift through its own influence on the proton equilibrium, which destabilizes kojic acid. Modern solutions include the individual encapsulation of one or both active ingredients, as well as the use of robust buffer systems based on sodium citrate or sodium gluconate, as described in the context of encapsulation and fermentation technologies.

Skincare Approach

Brightening complexes with tranexamic acid and kojic acid are typically formulated as serums or essences, as these galenics allow for precise active ingredient concentrations with a low occlusive film burden. Application is done mornings and/or evenings on cleansed skin — before moisturizer and, in the morning, before a broad-spectrum sunscreen (SPF 30+), as UV exposure immediately reactivates melanogenesis and counteracts any depigmenting effect. The topic of exfoliation is relevant in this context: regular, gentle peeling measures accelerate the shedding of melanin-containing corneocytes and can expedite the visibility of brightening effects. At the same time, aggressive exfoliation routines increase the risk of barrier disruption, which in turn promotes PIH through inflammatory stimuli — a trade-off that must be made individually.

In the context of layering: brightening serums with TXA/kojic acid complex are compatible with most routine active ingredients. Particular attention should be paid to the combination with AHA-containing products, as the low pH of alpha-hydroxy acid formulations (typically 3.0–4.0) can be temporarily beneficial for kojic acid stability, but immediate simultaneous application can compromise the skin barrier and promote irritation. A time lag (at least 20–30 minutes) or evening separation is recommended: AHA in the evening, TXA/kojic acid in the morning. With antioxidants such as vitamin C or ferulic acid, a synergistic combination is useful, as oxidative stress is a known melanogenesis trigger — here, it's worth looking at the findings on ferulic acid as an antioxidant booster. NATURFACTOR® integrates brightening active ingredient complexes into the Porcelain Skin Serum, which is based on precise pH control and a stable matrix formulation.

For individuals with sensitive skin, kojic acid should be used with caution: the substance can cause contact allergic reactions at concentrations above 1%, especially with prolonged use without barrier protection. Accompanying care with ceramides or beta-glucan can stabilize barrier function and minimize irritation risks.

Realistic Expectations

Clinical studies show improvements in the MASI score (Melasma Area and Severity Index) for topical tranexamic acid in melasma after 8–12 weeks of regular use, comparable to low-dose hydroquinone, but with a significantly more favorable tolerability profile. Kojic acid shows similar timeframes in controlled studies, although variability between individuals is considerable. In combination, accelerated or amplified effects are plausible but not proven by sufficiently large randomized controlled trials — combination studies exist, but are methodologically heterogeneous.

Continuity is crucial: brightening effects are not permanent. After discontinuation of the routine, re-pigmentation can occur within weeks with continued UV exposure. Long-term care with intermittent application (e.g., 3–4 times per week as maintenance therapy) combined with consistent sun protection is more realistic than the expectation of a one-time, permanent lightening. The Fitzpatrick skin type significantly influences how pronounced hyperpigmentation appears and how strong the therapeutic response is: darker phototypes (IV–VI) often show deeper melanin deposits in the dermis, which topical active ingredients are more difficult to reach.

Frequently Asked Questions

Can I use tranexamic acid and kojic acid simultaneously if they are in separate products?

Basically yes, but a time lag is advisable. Since both active ingredients can be formulated in different pH-optimized matrices, it is recommended to apply them sequentially in the layering order (thinner serum first), not simultaneously. Allow each product to absorb for a few minutes before applying the next to minimize uncontrolled pH interactions on the skin surface.

Why does my kojic acid product turn brownish?

Browning is a classic sign of kojic acid oxidation — triggered by increased pH, light, or heat exposure. An oxidized product has largely lost its depigmenting efficacy and should no longer be used. Pay attention to opaque, airtight packaging and store kojic acid-containing products in a cool place (15–20 °C). Encapsulated formulations are generally significantly more stable.

Is the combination with retinol advisable?

Retinol and its derivatives accelerate epidermal cell turnover and increase the penetration depth of other active ingredients — theoretically a synergistic approach. In practice, however, the combination significantly increases the risk of irritation, especially if exfoliants are also used. A gradual build-up of the routine and interval use (not both active ingredients daily at the same time) is recommended. People who are new to retinol will find a scientific classification in the article on Bakuchiol as a plant-based retinol equivalent — a milder alternative for beginners.

Conclusion

The combination of tranexamic acid and kojic acid in a brightening complex is scientifically sound and mechanistically coherent: both active ingredients act at different points in the melanogenesis cascade and complement each other in their spectrum of action. The greatest formulation challenge lies not in the biological incompatibility of the molecules, but in the pH drift problem of aqueous matrices, which particularly endangers the stability of kojic acid. High-quality brightening formulations solve this problem through precise buffer management, encapsulation technologies, and careful packaging selection. For users, this means: product quality, storage conditions, and continuity of application are at least as crucial as the choice of active ingredients themselves. Embedded in a well-thought-out routine — with consistent sun protection, barrier-strengthening moisture management, and needs-based exfoliation — a TXA/kojic acid complex unfolds its full depigmenting potential on an evidence-based basis.

1. Ebrahimi, B. & Naeini, F.F. (2014). Topical tranexamic acid as a promising treatment for melasma. Journal of Research in Medical Sciences, 19(8), 753–757.
2. Lim, J.T. (1999). Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatologic Surgery, 25(4), 282–284.
3. Sarkar, R., Chugh, S. & Garg, V.K. (2013). Newer and upcoming therapies for melasma. Indian Journal of Dermatology, Venereology and Leprology, 78(4), 417–428.
4. Sheth, V.M. & Pandya, A.G. (2011). Melasma: a comprehensive update. Journal of the American Academy of Dermatology, 65(4), 689–697.
5. Watanabe, T., Tokuda, Y. & Chiba, Y. (2021). Stability assessment of kojic acid in cosmetic formulations under varying pH conditions. International Journal of Cosmetic Science, 43(1), 45–53.